Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Weill Medical College of Cornell University
With
Genzyme, a Sanofi Company
A chart review will be completed on patients with multiple sclerosis to determine potential early characteristics that might be helpful in defining aggressive onset MS and predicting subsequent disease course and disability
Age
0–89
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Two or more relapses in the preceding year and 2 or more gadolinium enhancing lesions on brain MRI scan or a significant T 2 lesion burden or
One relapse if it results in sustained EDSS of 3.0 along with 2 or more gadolinium enhancing lesions or significant T2 lesion burden ( T2 lesion burden being determined by factoring the number of lesions, the size of the lesions and lesion location)
You may not be if
\-
Clareo Health | Aggressive Onset Multiple Sclerosis: A Practical Definition and Study of Its Clinical Course
